Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization turns negative
Q1 FY2026 depreciation & amortization was -$104K, compared with $23K a year earlier. Trailing-twelve-month depreciation & amortization was -$1.05M.
Context
- Depreciation & amortization amounted to 18.8% of revenue in FY2025, up 16.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -$104K or moves back toward the trailing-twelve-month quarterly average of -$261.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (1.88M) USD
- Year-over-year change
- -1468.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.88M) | -1468.6% |
| FY2024 | 2024-12-31 | 137K | +21.2% |
| FY2023 | 2023-12-31 | 113K | +44.9% |
| FY2022 | 2022-12-31 | 78K | — |
Depreciation & Amortization vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 depreciation & amortization of $1.05M is the 4th largest of the 8 companies compared; the peer median is $528K.
- Its year-over-year change of -922.8% is the lowest of 8, against a peer median of +0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $2.42M | +1.1% | — | — |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $2.39M | +1910.9% | — | 72.0% |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.05M | -922.8% | — | — | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
| LTM Sep 2026 | $378K | -10.0% | +28.4% | 5.3% | |
| LTM Mar 2026 | $305K | -36.9% | +1.9% | 0.6% | |
| FY2025 | $234K | +136.2% | +77.9% | — | |
| Peer median (excluding ZBIO) | $528K | +0.9% | +1.9% | 5.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.